Chris Boshoff takes on new role at Pfizer

US pharma giant Pfizer (NYSE: PFE) today announced that after a comprehensive internal and external selection process, the company is appointing Dr Chris Boshoff, as chief scientific officer and president, research and Development effective January 1, 2025.

Dr Boshoff, who most recently served as chief oncology officer and executive vice president, will succeed Dr Mikael Dolsten whose departure from Pfizer was announced earlier this year. In his new role, Dr Boshoff will remain a member of Pfizer’s executive leadership team reporting to chairman and chief executive Dr Albert Bourla, and he will oversee all functions of R&D across all therapeutic areas. During his more than 11 years at Pfizer, Dr Boshoff has delivered an impressive 24 approved innovative medicines and biosimilars in more than 30 indications.

Pfizer’s Oncology R&D organization will maintain its fully integrated structure with Dr Roger Dansey serving as interim chief oncology officer, reporting to Dr Boshoff effective January 1, 2025. Dr Dansey will assist Dr Boshoff in selecting a permanent chief oncology officer, after which time he will retire from Pfizer. He will also facilitate a smooth transition of his current responsibilities to his successor, Dr Johanna Bendell, who will be joining Pfizer from Roche (ROG: SIX) in 2025 as chief development officer, oncology.